Pfizer and BioNTech are collaborating to create a new mRNA vaccine, this time for shingles.
The shingles project is the third vaccine collaboration between the two companies, as they began an influenza vaccine collaboration in 2018 and a COVID-19 vaccine collaboration in 2020, according to a Jan. 5 news release.
The vaccine will be based on BioNTech’s mRNA platform and Pfizer’s antigen technology, the companies said. Under the deal, Pfizer will pay BioNTech $225 million and BioNTech will pay Pfizer $25 million.
The companies expect clinical trials to begin in the second half of 2022.
Read more about the collaboration here.